Charles Schwab Investment Management Inc. Reduces Holdings in Lyell Immunopharma, Inc. $LYEL

Charles Schwab Investment Management Inc. decreased its position in Lyell Immunopharma, Inc. (NASDAQ:LYEL) by 2.5% during the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 1,604,676 shares of the company’s stock after selling 41,111 shares during the period. Charles Schwab Investment Management Inc. owned about 0.54% of Lyell Immunopharma worth $863,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Graham Capital Management L.P. purchased a new stake in Lyell Immunopharma during the 4th quarter valued at $33,000. Wells Fargo & Company MN boosted its position in Lyell Immunopharma by 27.8% during the 4th quarter. Wells Fargo & Company MN now owns 94,320 shares of the company’s stock valued at $60,000 after buying an additional 20,542 shares during the period. Public Employees Retirement System of Ohio purchased a new stake in Lyell Immunopharma during the 4th quarter valued at $64,000. Exchange Traded Concepts LLC boosted its position in Lyell Immunopharma by 82.4% during the 1st quarter. Exchange Traded Concepts LLC now owns 246,349 shares of the company’s stock valued at $133,000 after buying an additional 111,299 shares during the period. Finally, BNP Paribas Financial Markets purchased a new stake in Lyell Immunopharma during the 4th quarter valued at $162,000. 66.05% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the stock. Wall Street Zen raised shares of Lyell Immunopharma from a “sell” rating to a “hold” rating in a research report on Monday. HC Wainwright reiterated a “neutral” rating and set a $10.00 price target on shares of Lyell Immunopharma in a research report on Tuesday, June 24th. One investment analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Lyell Immunopharma presently has an average rating of “Reduce” and an average target price of $15.00.

Lyell Immunopharma Stock Performance

Shares of NASDAQ LYEL opened at $11.41 on Wednesday. The firm’s 50 day moving average price is $10.52 and its 200-day moving average price is $10.33. The company has a market cap of $219.19 million, a PE ratio of -0.47 and a beta of -0.19. Lyell Immunopharma, Inc. has a 52-week low of $7.65 and a 52-week high of $32.00.

Lyell Immunopharma (NASDAQ:LYEL) last issued its earnings results on Tuesday, August 12th. The company reported ($2.89) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.80) by $0.91. Lyell Immunopharma had a negative net margin of 552,328.31% and a negative return on equity of 85.58%. The firm had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.00 million. On average, analysts forecast that Lyell Immunopharma, Inc. will post -0.78 earnings per share for the current fiscal year.

Lyell Immunopharma Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.